Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12821007 | 1.00 | CES2 (0.40) | CES2TAS2R46 | |
| SCHEMBL13771160 | 1.00 | CES2 (0.40) | CES2TAS2R46 | |
| SCHEMBL12305441 | 1.00 | CES2 (0.40) | CES2TAS2R46 | |
| SCHEMBL1446617 | 1.00 | CES2 (0.40) | CES2TAS2R46 | |
| SCHEMBL10042111 | 1.00 | CES2 (0.40) | CES2TAS2R46 | |
| SCHEMBL18780386 | 1.00 | CES2 (0.40) | CES2TAS2R46 | |
| Hydrogen Peroxide SCHEMBL5076367 | 1.00 | CES2 (0.40) | CES2TAS2R46 | |
| SCHEMBL13770795 | 1.00 | CES2 (0.40) | CES2TAS2R46 | |
| SCHEMBL13771155 | 1.00 | CES2 (0.40) | CES2TAS2R46 | |
| SCHEMBL18950962 | 1.00 | CES2 (0.40) | CES2TAS2R46 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241023-A1 | STABILIZATION OF 1,2,4-TRIOXANE COMPOUNDS BY CHLOROGENIC ACIDS | Artemiflow GmbH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241023-A1 | STABILIZATION OF 1,2,4-TRIOXANE COMPOUNDS BY CHLOROGENIC ACIDS | Artemiflow GmbH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230149346-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | Artemiflow GmbH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230149346-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | Artemiflow GmbH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20210292296-A1 | 1,2,4-Trioxane compounds and compositions comprising the same for use in the treatment of COVID-19 | Artemiflow GmbH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210187468-A1 | MODULAR CONTINOUS FLOW DEVICE | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2021-06-24 | — | — | US | disclosed |
| EP-3386628-B1 | MODULAR CONTINUOUS FLOW DEVICE | MAX PLANCK GESELLSCHAFT (DE) | 2019-06-12 | — | — | EP | disclosed |
| US-9802952-B2 | Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives | Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.v. (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9802952-B2 | Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives | Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.v. (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-3210667-A1 | MODULAR CONTINUOUS FLOW DEVICE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-20150328617-A1 | METHOD AND DEVICE FOR THE SYNTHESIS OF ARTEMISININ | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-11-19 | — | — | US | disclosed |
| US-20150328617-A1 | METHOD AND DEVICE FOR THE SYNTHESIS OF ARTEMISININ | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-11-19 | — | — | US | disclosed |
| US-9150535-B2 | Method and device for the synthesis of artemisinin | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150535-B2 | Method and device for the synthesis of artemisinin | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-10-06 | — | — | US | disclosed |
| WO-2015007693-A1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-22 | — | — | WO | disclosed |
| EP-2826779-A1 | Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-20140364630-A1 | METHOD AND DEVICE FOR THE SYNTHESIS OF ARTEMISININ | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) | 2014-12-11 | — | — | US | disclosed |
| US-20140364630-A1 | METHOD AND DEVICE FOR THE SYNTHESIS OF ARTEMISININ | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) | 2014-12-11 | — | — | US | disclosed |
| WO-2013030247-A1 | METHOD AND DEVICE FOR THE SYNTHESIS OF ARTEMISININ | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-03-07 | — | — | WO | disclosed |
| EP-2565197-A1 | Method and device for the synthesis of artemisinin | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149346-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | PRDX4, CA4, TOP1 | CES2 2616/4885TAS2R46 2354/4885 |
| US-20230241023-A1 | STABILIZATION OF 1,2,4-TRIOXANE COMPOUNDS BY CHLOROGENIC ACIDS | GCK, PCK1, CA4 | CES2 1349/4885TAS2R46 2526/4885 |
| US-20210187468-A1 | MODULAR CONTINOUS FLOW DEVICE | COASY, DCXR, TKFC | CES2 2958/4885TAS2R46 4376/4885 |
| US-20140364630-A1 | METHOD AND DEVICE FOR THE SYNTHESIS OF ARTEMISININ | DHFR, DHODH, DHPS | CES2 3400/4885TAS2R46 3945/4885 |
| US-20210292296-A1 | 1,2,4-Trioxane compounds and compositions comprising the same for use in the treatment of COVID-19 | ACE2, ACE, DDX18 | CES2 2763/4885TAS2R46 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.